Boc-L-Asp(tBu)-ONp

Boc-L-Asp(tBu)-ONp is a Boc-protected L-aspartic acid derivative bearing a tert-butyl-protected side-chain carboxyl group and an active ONp (p-nitrophenyl) ester at the C-terminus, making it a purpose-built amino acid building block for peptide coupling. This electrophilic ester form is widely used to generate amide bonds under peptide synthesis conditions, while the Boc group and tBu side-chain protection help maintain chemoselectivity during assembly of Asp-containing sequences. Researchers and developers commonly select this specific protection pattern when they need reliable reactivity from the ONp ester without exposing the side-chain carboxylate.

1. Peptide Coupling Building Block

Boc-L-Asp(tBu)-ONp is used as an activated aspartate building block for forming peptide bonds in both solution-phase peptide synthesis and custom segment condensation workflows. The ONp ester provides a convenient leaving group for amide-bond formation with amine partners, enabling efficient coupling during assembly of Asp-containing peptides where the side-chain carboxyl must remain protected. Peptide synthesis groups and contract peptide manufacturers often choose the Boc/tBu/ONp protection scheme to balance coupling reactivity with side-chain stability, supporting downstream deprotection and purification steps in standard peptide workflows.

2. Aspartate-Containing Segment Synthesis

Boc-L-Asp(tBu)-ONp is particularly relevant for preparing aspartate-rich peptide segments and for assembling longer sequences where controlled handling of the Asp side chain is critical. The tert-butyl protection on the side-chain carboxyl helps prevent unwanted side reactions during segment assembly, while the Boc group supports orthogonal deprotection strategies later in the synthesis cycle. This makes the reagent a practical choice for researchers building peptides for structure-function studies, where sequence fidelity and minimizing side-chain interference during condensation are key priorities.

3. Pharmaceutical Peptide Intermediate Development

Boc-L-Asp(tBu)-ONp is also used in pharmaceutical intermediate development for producing protected peptide intermediates that can be further elaborated into advanced candidates or formulation-relevant constructs. Development chemists rely on activated amino acid ester building blocks to streamline the conversion from protected fragments into defined amide linkages, while the established Boc and tBu protection pattern supports predictable downstream deprotection logic. In this context, the ONp ester functionality is valued for enabling coupling steps that integrate cleanly into iterative intermediate synthesis and purification workflows used in medicinal chemistry programs.

4. Solid-Phase Peptide Synthesis Support

Boc-L-Asp(tBu)-ONp is frequently employed as a coupling reagent/activated amino acid component in workflows that generate Asp-containing sequences with protected side chains, including approaches that combine solution-phase fragment preparation with subsequent solid-phase steps. The ONp ester activation supports efficient amide bond formation with appropriate nucleophiles, while Boc and tBu protections help maintain the integrity of the Asp residue during iterative assembly. Peptide chemistry teams use this reagent when they want a defined, reactive Asp building block that fits into established coupling and deprotection schedules for producing protected peptide sequences for later characterization and final processing.

1. Uncarboxylated osteocalcin decreases insulin-stimulated glucose uptake without affecting insulin signaling and regulators of mitochondrial biogenesis in myotubes

2. Odorant binding protein based biomimetic sensors for detection of alcohols associated with Salmonella contamination in packaged beef

3. A possible role of tachykinin-related peptide on an immune system activity of mealworm beetle, Tenebrio molitor L

4. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists

5. An Isolated TCR αβ Restricted by HLA-A* 02: 01/CT37 Peptide Redirecting CD8+ T Cells to Kill and Secrete IFN-γ in Response to Lung Adenocarcinoma Cell Lines